Approved comparison material connected to this topic.
16 total recordsSource comparisons are presented without a generated winner.
Starting Dose 0.25mg 0.05mL (5 units) Tolerance assessment, first 5 days Minimal visible change; receptor priming phase 10–15% mild nausea, typically resolves within 48 hours Essential baseline. Skipping this …
Dose per administration 16mg subcutaneous implant 0.25–1mg daily SC injection (extrapolated, not validated) Variable. No standardised EPP protocol exists Implant dosing is the only FDA/EMA-approved regimen wit…
Melanotan-1 (the original peptide sequence) and afamelanotide (the FDA- and EMA-approved drug) are not interchangeable terms, though they're often conflated online. Afamelanotide ([Nle4, D-Phe7]-α-MSH) is a 13…
Melanotan-1 follows a two-phase dosing model because melanocyte stimulation requires sustained receptor activation over multiple days before eumelanin density reaches photoprotective levels. The loading phase …
Standard Loading (0.16mg/kg × 5 days, then maintenance every 48–72h) Daily × 5 days, then every 48–72h Fitzpatrick I–III, functional MC1R 2–3× baseline Nausea 15–20%, flushing 10% The validated clinical protoc…
10mg 1mL 10mg/mL 0.05mL (5 units) 0.1mL (10 units) 10 doses Highest concentration. Smallest injection volume but requires precise syringe control; optimal for researchers prioritising injection frequency over …
The loading phase establishes baseline melanin density before UV exposure begins. Clinical protocols use 0.16–0.25mg/kg daily for 10–14 days. For a 70kg individual, this translates to approximately 250–350mcg …
Clinical EPP Protocol (Scenesse Equivalent) 250–350mcg (0.16–0.25mg/kg for 70kg individual) 10–14 days before UV exposure Controlled UV at 70–80% MED, 2–3× weekly during loading 250mcg every other day or 175mc…
Loading 0.16 9.6mg/day 12mg/day 14.4mg/day Daily 10 days MC1R saturation, eumelanin induction Maintenance 0.08 4.8mg/dose 6mg/dose 7.2mg/dose Every 48h 8–12 weeks Sustained receptor occupancy, photoprotection …
| Phase | Daily Dose | Duration | Injection Frequency | Expected Pigmentation Change | Primary Goal | Professional Assessment ||—|—|—|—|—|—|| Load | 0.25mg | 7–10 days | Once daily, 6–8 AM | Minimal visible ch…
Phototype I–II (pale, red hair, MC1R variants) 0.05–0.08 Every 72–96 hours 0.02–0.025 Weekly 14–21 days Higher doses required due to reduced MC1R function. Start conservatively and titrate based on response Ph…
0.08mg/kg (Initial Titration) 5.6mg subcutaneous 20–30 days partial protection <5% 8–12% first dose Phase 2 safety data Subtherapeutic for most EPP patients. Use only as dose 1 in titration 0.16mg/kg (Standard…
Standard Clinical Titration 0.25mg → 1.0mg over 10 days 14–21 days 0.5mg twice weekly Nausea 40%, flushing 30% (week 1 only) Gold standard. Minimizes side effects while achieving reliable melanogenesis within …
Researchers calculate Melanotan-1 dosage using three primary methods, each with distinct precision and complexity tradeoffs. The table below compares fixed-volume reconstitution, body-weight-adjusted dosing, a…
This comparison table categorizes common Melanotan-1 research applications by dose range, administration frequency, and primary outcome measures. Protocols vary based on target receptor pathways and study dura…
Type I–II (Very fair, burns easily) 0.25–0.5mg for 14 days 0.5mg 2–3×/week 10–14 days Nausea 20–30%, flushing common Start low. MC1R sensitivity highest in fair skin; aggressive dosing offers no timeline advan…